Leukemia patients can develop resistance to the one drug that is keeping their cancer at bay. Now two new drugs may be able to help.
The drug Gleevec has been considered the standard for treatment of certain kinds of leukemia, however many patients develop genetic mutations that do not allow their body to respond to the drug. Now two new drugs being tested, Dasatinib and Nilotinib, they have been shown to reverse the symptoms of leukemia in patients who no longer respond to Gleevec.
For example, eleven of the twelve patients with early-stage leukemia who took Nilotinib went into complete remission. Both drugs did not have serious side effects. They will soon be up for approval by the FDA.
Experts say about five thousand patients are affected by leukemia each year in the US. Novartis is developing Nilotinib, Bristol Myers Squibb is developing Dasatinib. Both drugs worked differently in the several stages of disease.
AIDS-related deaths worldwide have been halved since 2005 as more people were able to get lifesaving drugs, UNAIDS (a United Nations Program) says in a new report.
Americans traveling to Europe should take steps to protect themselves against measles, the U.S. Centers for Disease Control and Prevention advises.
Women exposed to estrogen for longer periods of time during the reproductive years may have a lower risk of depression, a new study finds.
People who undergo knee surgery for a torn anterior cruciate ligament (ACL) can expect to stay active and maintain a high quality of life, researchers report.